This article, the second and concluding one in the series, describes the epidemiological approach to drug research and control and the means now being developed—the expertise, the data stores, the lines of communication, the modes of discipline—for effectuating the approach. It then considers the implications of this evolution for the drug industry and for investment choice among drug companies.